Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

NCT03539822 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

117

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
Esophageal Adenocarcinoma
Hepatocellular Carcinoma
Colorectal Cancer

Interventions

DRUG: Cabozantinib
DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

Anwaar Saeed

Collaborators

[object Object]
[object Object]